Lv5
1530 积分 2023-08-11 加入
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
19小时前
待确认
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):a randomised, double-blind, placebo-controlled, phase 3 trial Regorafenib
1天前
待确认
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
1天前
待确认
Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
1天前
待确认
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
2天前
已完结
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
3天前
已完结
[Diagnosis and treatment of non-alcoholic fatty liver disease]
3天前
求助中
Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins
1个月前
已完结
A Qualitative Analysis of Patient Perspectives and Preferences in Lupus Management to Guide Lupus Guidelines Development
1个月前
已完结
Nanoparticle detection of respiratory infection
1个月前
已完结
皖公网安备34019202002308
